Skip to main content
letter
. 2003 Jun 10;88(12):2002–2003. doi: 10.1038/sj.bjc.6600950

Table 1. Prevalence of anti-HPV-16 antibodies among cases and controls.

Diagnosis Percentage with anti-HPV-16 antibodies (number positive/total) Percentage with medium titres of anti-HPV-16 antibodies (number positive/total) Percentage with high titres of anti-HPV-16 antibodies (number positive/total)
All Subjects      
 Controls 16% (6/31) 14% (5/37) 3% (1/37)
  Cases      
  Total 15% (37/254) 8% (21/254) 6% (16/254)
  CIN I 18% (5/28) 11% (3/28) 7% (2/28)
  CIN II 15% (5/34) 12% (4/34) 3% (1/34)
  CIN III 14% (12/84) 7% (6/84) 7% (6/84)
  Invasive 14% (15/108) 7% (8/108) 6% (7/108)
       
HIV-seronegative subjects      
 Controls 21% (5/24) 17% (4/24) 4% (1/24)
  Cases      
  Total 15% (13/85) 8% (7/85) 7% (6/85)
  CIN I 8% (1/12) 0% (0/12) 8% (1/12)
  CIN II 9% (1/11) 0% (0/11) 9% (1/11)
  CIN III 17% (5/29) 10% (3/29) 7% (2/29)
  Invasive 18% (6/33) 12% (4/33) 6% (2/33)
       
HIV-seropositive subjects      
 Controls 8% (1/13) 8% (1/13) 0% (0/13)
  Cases      
  Total 14% (24/169) 8% (14/169)  
  CIN I 25% (4/16) 19% (3/16) 6% (10/169)
  CIN II 17% (4/23) 17% (4/23) 6% (1/16)
  CIN III 13% (7/55) 5% (3/55) 0% (0/23)
  Invasive 12% (9/75) 5% (4/75) 7% (4/55)